Effects of the sodium‐glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan
Ken Ohara(Jichi Medical University), Daisuke Nagata(Jichi Medical University), Atsushi Miki(Jichi Medical University), Akito Maeshima(Social Insurance Saitama Chuo Hospital), Yasuharu Miyazawa(Sapporo Minami Hospital), Mari Okada(Seoul National University Children's Hospital), Takahiro Masuda(Jichi Medical University), Osamu Saitô(Institute for Global Environmental Strategies), Tetsu Akimoto(Jichi Medical University), Taro Sugase(Jichi Medical University), Akihiro Myoga(Jichi Medical University), Chuji Sekiguchi(Sapporo Minami Hospital), Shigeaki Muto(Jichi Medical University), Saki Nakagawa(Okayama University), Toshimi Imai(Jichi Medical University), Takuya Murakami(Jichi Medical University), Hiromichi Yoshizawa(Jichi Medical University)
Cited by 82
Related Papers
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
AMP-activated Protein Kinase (AMPK) Signaling in Endothelial Cells Is Essential for Angiogenesis in Response to Hypoxic Stress
|Journal of Biological Chemistry|2003|328
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality
|Renal Replacement Therapy|2020|170
Ligand-induced rearrangement of the dimeric metabotropic glutamate receptor 1α
|Nature Structural & Molecular Biology|2004|161